Indications for: SHINGRIX

Prevention of herpes zoster (shingles): in adults ≥50yrs of age; or in adults ≥18yrs of age at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.

Limitations of Use:

Not for preventing primary varicella infection (chickenpox).

Adult Dosage:

Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose given between 2–6 months later. Immunocompromised (≥18yrs): one 0.5mL dose at Month 0 followed by second dose given between 1–2 months later.

Children Dosage:

<18yrs: not established.

SHINGRIX Contraindications:

Allergies to any previous Shingrix vaccination.

SHINGRIX Warnings/Precautions:

Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Syncope. Pregnancy. Nursing mothers.

SHINGRIX Classification:

Shingles vaccine.

SHINGRIX Interactions:

Concomitant influenza vaccines: see full labeling.

Adverse Reactions:

Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms; Guillain-Barre syndrome, transient neurological effects.


To report adverse events, contact VAERS at (800) 822-7967.

Generic Drug Availability:


How Supplied:

Single-dose vials—1, 10 (antigen + adjuvant components)